Evidence map›Paper›PMID 35759017›Full record

ArticleEuropean radiology2022

Survival outcome assessment for triple-negative breast cancer: a nomogram analysis based on integrated clinicopathological, sonographic, and mammographic characteristics.

Dan-Li Sheng, Xi-Gang Shen, Zhao-Ting Shi, Cai Chang, Jia-Wei Li

Open access · hybridAbstract read
In one paragraph

Article in European radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Dan-Li Sheng *Department of Medical Ultrasound, Fudan University Shanghai Cancer Center, No 270, Dong'an Road, Xuhui District, Shanghai, 200032, China.
Xi-Gang Shen *Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Zhao-Ting ShiDepartment of Medical Ultrasound, Fudan University Shanghai Cancer Center, No 270, Dong'an Road, Xuhui District, Shanghai, 200032, China.
Cai ChangDepartment of Medical Ultrasound, Fudan University Shanghai Cancer Center, No 270, Dong'an Road, Xuhui District, Shanghai, 200032, China. changc61@163.com.
Jia-Wei LiDepartment of Medical Ultrasound, Fudan University Shanghai Cancer Center, No 270, Dong'an Road, Xuhui District, Shanghai, 200032, China. jiaweili2006@163.com.ORCID http://orcid.org/0000-0003-4270-0681
Shanghai Medical College of Fudan University · CN

Funding

National Natural Science Foundation of China 81627804National Natural Science Foundation of China 81830058National Natural Science Foundation of China 81901760National Natural Science Foundation of China 82102070Shanghai Anticancer Association SOAR Project SACA-AX201905Shanghai Science and Technology Foundation of China 18411967400
6 · The paper itself

Abstract

objectiveThis study aimed to incorporate clinicopathological, sonographic, and mammographic characteristics to construct and validate a nomogram model for predicting disease-free survival (DFS) in patients with triple-negative breast cancer (TNBC).

methodsPatients diagnosed with TNBC at our institution between 2011 and 2015 were retrospectively evaluated. A nomogram model was generated based on clinicopathological, sonographic, and mammographic variables that were associated with 1-, 3-, and 5-year DFS determined by multivariate logistic regression analysis in the training set. The nomogram model was validated according to the concordance index (C-index) and calibration curves in the validation set.

resultsA total of 636 TNBC patients were enrolled and divided into training cohort (n = 446) and validation cohort (n = 190). Clinical factors including tumor size > 2 cm, axillary dissection, presence of LVI, and sonographic features such as angular/spiculated margins, posterior acoustic shadows, and presence of suspicious lymph nodes on preoperative US showed a tendency towards worse DFS. The multivariate analysis showed that no adjuvant chemotherapy (HR = 6.7, 95% CI: 2.6, 17.5, p < 0.0005), higher axillary tumor burden (HR = 2.7, 95% CI: 1.0, 7.1, p = 0.045), and ≥ 3 malignant features on ultrasound (HR = 2.4, CI: 1.1, 5.0, p = 0.021) were identified as independent prognostic factors associated with poorer DFS outcomes. In the nomogram, the C-index was 0.693 for the training cohort and 0.694 for the validation cohort. The calibration plots also exhibited excellent consistency between the nomogram-predicted and actual survival probabilities in both the training and validation cohorts.

conclusionsClinical variables and sonographic features were correlated with the prognosis of TNBCs. The nomogram model based on three variables including no adjuvant chemotherapy, higher axillary tumor load, and more malignant sonographic features showed good predictive performance for poor survival outcomes of TNBC. KEY POINTS: • The absence of adjuvant chemotherapy, heavy axillary tumor load, and malignant-like sonographic features can predict DFS in patients with TNBC. • Mammographic features of TNBC could not predict the survival outcomes of patients with TNBC. • The nomogram integrating clinicopathological and sonographic characteristics is a reliable predictive model for the prognostic outcome of TNBC.

Indexed as

NomogramsTriple Negative Breast NeoplasmsDisease-Free SurvivalHumansPrognosisRetrospective StudiesDisease-free survivalMammographyNomogramsTriple-negative breast neoplasmsUltrasonography

Identifiers

PMID35759017
PMCPMC9474369
OpenAlexW4283588198

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.